Formulation and evaluation of Oxybutynin chloride loaded proniosomal gel for transdermal drug delivery

Clinical utility of Oxybutynin chloride is restricted due common side effects viz., its dry mouth, and difficulty in micturition, constipation, blurred vision, drowsiness, and dizziness. This study evaluated the prospective of proniosomal gel to improve the clinical efficacy of Oxybutynin chloride and compare with oral therapy. A series of Viz., B1 to B8 Proniosomal gel were prepared by phase separation and coaccervation method using different proportions of Span (span 60, span 40, span 80, span 20): Cholesterol: Soya lecithin, further characterized for vesicle size, zeta potential and entrapment efficiency, In vitro drug release. The B2 formulation exhibited nano size with high entrapment efficiency, adequate zeta potential, greater transdermal flux and better stability (at refrigerated conditions). Release profile of B2 displayed anomalous behavior and release mechanism was indicative of diffusion controlled. The study concludes that transdermal route is an ideal for Oxybutynin chloride with improved clinical efficacy.